X4 Pharmaceuticals (XFOR) Return on Sales (2018 - 2025)
X4 Pharmaceuticals (XFOR) reported Return on Sales of 0.09% for Q4 2025, up 18.0% on a YoY basis from 0.08% in Q4 2024, and up 44.85% quarter-over-quarter from 0.17% in Q3 2025.
X4 Pharmaceuticals (XFOR) Return on Sales (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Return on Sales for 5 years, with the latest figure at 0.09% in Q4 2025.
- For the quarter ending Q4 2025, Return on Sales rose 18.0% year-over-year to 0.09%; the trailing twelve-month figure through Dec 2025 stood at 0.02% (up 12.0% YoY), and the FY2025 full-year result was 0.02%, up 12.0% from the prior year.
- Return on Sales for Q4 2025 stood at 0.09%, up from 0.17% in the prior quarter.
- The five-year high for Return on Sales was 1.61% in Q2 2024, with the low at 0.66% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.00% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 0.00% |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | -0.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.09% |
| Sep 30, 2025 | -0.17% |
| Jun 30, 2025 | -0.13% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | -0.28% |
| Sep 30, 2024 | -0.66% |
| Jun 30, 2024 | 1.61% |
| Dec 31, 2020 | -0.21% |
| Sep 30, 2020 | -0.18% |
| Jun 30, 2020 | -0.18% |
| Mar 31, 2020 | -0.04% |
| Sep 30, 2019 | -0.14% |
| Dec 31, 2018 | -0.02% |